Intravenous immunoglobulins: In-depth review of eExcipients and acute kidney injury risk

American Journal of Nephrology

Volumn 38, Issue 4, 2013, Pages 275-284

  Dantal, Jacques ^a  

^a HÔTEL DIEU   (France)

Author keywords

Acute kidney injury; Adverse drug reactions; Intravenous immunoglobulins; Renal failure; Side effects

Indexed keywords

CLAIRYG; CREATININE; EXCIPIENT; GAMMAKED; GAMUNEX C; GLYCINE; HUMAN IMMUNOGLOBULIN; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; PROLINE; UNCLASSIFIED DRUG; GLUCOSE; MALTOSE; MANNITOL; SORBITOL; SUCROSE;

ACUTE KIDNEY FAILURE; ANURIA; ARTICLE; COMORBIDITY; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DRUG SURVEILLANCE PROGRAM; HEMATURIA; HEMOGLOBINURIA; HEMOLYSIS; HEMOLYTIC ANEMIA; HUMAN; HYPONATREMIA; INTERSTITIAL NEPHRITIS; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; KIDNEY TUBULE DISORDER; MEDICAL HISTORY; NEPHROSIS; NEPHROTOXICITY; OFF LABEL DRUG USE; OLIGURIA; PRIORITY JOURNAL; RISK FACTOR; SYSTEMATIC REVIEW; BRUSH BORDER; CELL VACUOLE; DIABETIC PATIENT; GLOMERULUS EPITHELIUM CELL; KIDNEY PROXIMAL TUBULE; METABOLIC CAPACITY; NONHUMAN; PATHOGENESIS; REVIEW;

ACUTE KIDNEY INJURY; COMORBIDITY; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; EXCIPIENTS; GLYCINE; HEMOLYSIS; HUMANS; HYDROGEN-ION CONCENTRATION; IMMUNOGLOBULINS, INTRAVENOUS; INCIDENCE; KIDNEY; MALTOSE; PROLINE; SORBITOL; SUCROSE;

EID: 84887114204     PISSN: 02508095     EISSN: 14219670     Source Type: Journal    
DOI: 10.1159/000354893     Document Type: Article

References (82)

1. Mark SM: Comparison of intravenous immunoglobulin formulations: product, formulary, and cost considerations. Hosp Pharm 2011; 46: 668-679.
2. Siegel J: Immune globulins: therapeutic, pharmaceutical, cost, and administration considerations. Pharmacy Practice News, Special Edition, October 2011.
3. Leong H, Stachnik J, Bonk ME, Matuszewski KA: Unlabeled uses of intravenous immune globulin. Am J Health Syst Pharm 2008; 65: 1815-1824.
4. Orange JS, Hossny EM, Weiler CR, et al: Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol 2006; 117(suppl):S525-S553.
5. Ratko TA, Burnett DA, Foulke GE, Matuszewski KA, Sacher RA: Recommendations for off-label use of intravenously administered immunoglobulin preparations. University Hospital Consortium Expert Panel for Off- Label Use of Polyvalent Intravenously Administered Immunoglobulin Preparations. JAMA 1995; 273: 1865-1870.
6. Wimperis J, Lunn M, Jones A, et al: Clinical guidelines for immunoglobulin use. Second edition update. 2011. http://www.dh.gov.uk/ prodconsumdh/groups/dhdigitalassets/ documents/digitalasset/dh131107.pdf (accessed September 21, 2012).
7. Agence Nationale de Sé curité du Mé dicament et des Produits de Santé : Octagam 100 mg/ml, solution pour perfusion. http://ansm.sante.fr/ Dossiers-thematiques/Referentiels-de-bonusage- des-medicaments/Immunoglobulines/ Tableau-immunoglobulines/OCTAGAM- 100-mg-ml-solution-pour-perfusion (accessed September 21, 2012).
8. Anderson D, Ali K, Blanchette V, et al: Guidelines on the use of intravenous immune globulin for hematologic conditions. Transfus Med Rev 2007; 21(suppl 1):S9-S56.
9. Feasby T, Banwell B, Benstead T, et al: Guidelines on the use of intravenous immune globulin for neurologicconditions. Transfus Med Rev 2007; 21(suppl 1):S57-S107.
10. Group APIIE. Consensus recommendations for the use of immunoglobulin replacement therapy in immune deficiency. 2009. http:// www.info4pi.org/ Documents/Publications/ APIIEG%20Consensus%20Recommenda tions%20Edition%202%20July%20200920120201170745.pdf (accessed September 21, 2012).
11. Immune Deficiency Foundation: Treatment experiences and preferences of patients with primary immune deficiency diseases: First national survey. 2003;http://primary immune. org/idf-survey-research-center/idf-surveys (accessed February 28, 2012).
12. Itkin YM, Trujillo TC: Intravenous immunoglobulin- associated acute renal failure: case series and literature review. Pharmacotherapy 2005; 25: 886-892.
13. Williams AK, Ward LG, Bhatt VK: IVIG use in renal insufficiency or transplantation. US Pharm 2010; 35:HS19-HS25.
14. Cayco AV, Perazella MA, Hayslett JP: Renal insufficiency after intravenous immune globulin therapy: a report of two cases and an analysis of the literature. J Am Soc Nephrol 1997; 8: 1788-1794.
15. Chapman SA, Gilkerson KL, Davin TD, Pritzker MR: Acute renal failure and intravenous immune globulin: occurs with sucrose-stabilized, but not with D -sorbitol-stabilized, formulation. Ann Pharmacother 2004; 38: 2059-2067.
16. Shah S, Vervan M: Use of intravenous immune globulin and occurrence of associated acute renal failure and thrombosis. Am J Health Syst Pharm 2005; 62: 720-725.
17. Center for Biologics Evaluation and Research: Dear Doctor Letter: Important Drug Warning - Acute Renal Failure Associated with Immune Globulin Intravenous (Human). Bethesda, US FDA, 1999.
18. Moulis G, Sailler L, Sommet A, Lapeyre- Mestre M, Montastruc JL: Exposure to inhibitors of the renin-angiotensin system is a major independent risk factor for acute renal failure induced by sucrose-containing intravenous immunoglobulins: a case-control study. Pharmacoepidemiol Drug Saf 2012; 21: 314-319.
19. Siegel J: IVIG medication safety: a stepwise guide to product selection and use. Pharmacy Practice News, Special Edition, October 2011.
20. Centers for Disease Control and Prevention: Renal insufficiency and failure associated with immune globulin intravenous therapy - United States, 1985-1998. MMWR 1999; 48: 518-521.
21. Orbach H, Tishler M, Shoenfeld Y: Intravenous immunoglobulin and the kidney - a two-edged sword. Semin Arthritis Rheum 2004; 34: 593-601.
22. Lin RY, Rodriguez-Baez G, Bhargave GA, Lin H: Intravenous gammaglobulin-associated renal impairment reported to the FDA: 2004- 2009. Clin Nephrol 2011; 76: 365-372.
23. US Department of Health and Human Services: Analysis of supply, distribution, demand, and access issues associated with immune globulin intravenous (IGIV). 2007. http://aspe.hhs.gov/sp/reports/2007/IGIV/report.pdf (accessed May 31, 2012).
24. Robert P: IVIG/SCIG: Global Usage Trends 2011.
25. Schulz G: Markets, milestones, perspectives. 2006. http://www.more-ir.de/ download/companies/biotest/Other%20Information/biotest060320schulz.pdf (accessed May 31, 2012).
26. Agence Française de Sé curité Sanitaire des Produits de Santé . Commission Nationale dePharmacovigilance, 2006.
27. Haskin JA, Warner DJ, Blank DU: Acute renal failure after large doses of intravenous immune globulin. Ann Pharmacother 1999; 33: 800-803.
28. Ahsan N: Intravenous immunoglobulin-induced nephropathy: a complication of IVIG therapy. J Nephrol 1998; 11: 157-161.
29. Cantu TG, Hoehn-Saric EW, Burgess KM, Racusen L, Scheel PJ: Acute renal failure associated with immunoglobulin therapy. Am J Kidney Dis 1995; 25: 228-234.
30. Graumann A, Zawada ET Jr: Case report: acute renal failure after administering intravenous immunoglobulin. Postgrad Med 2010; 122: 142-147.
31. Laidlaw S, Bainton R, Wilkie M, Makris M: Acute renal failure in acquired haemophilia following the use of high-dose intravenous immunoglobulin. Haemophilia 1999; 5: 270-272.
32. Rault R, Piraino B, Johnston JR, Oral A: Pulmonary and renal toxicity of intravenous immunoglobulin. Clin Nephrol 1991; 36: 83-86.
33. Donataccio M, Dalle Ore G, Donataccio D: Acute renal failure following intravenous administration of hepatitis B immunoglobulin in liver transplantation. Minerva Gastroenterol Dietol 2009; 55: 501-504.
34. Hansen-Schmidt S, Silomon J, Keller F: Osmotic nephrosis due to high-dose immunoglobulin therapy containing sucrose (but not with glycine) in a patient with immunoglobulin A nephritis. Am J Kidney Dis 1996; 28: 451-453.
35. Chacko B, John GT, Balakrishnan N, Kirubakaran MG, Jacob CK: Osmotic nephropathy resulting from maltose-based intravenous immunoglobulin therapy. Ren Fail 2006; 28: 193-195.
36. Horn J, Thon V, Bartonkova D, et al: Anti-IgA antibodies in common variable immunodeficiency (CVID): diagnostic workup and therapeutic strategy. Clin Immunol 2007; 122: 156-162.
37. Kwan TH, Tong MK, Siu YP, et al: Acute renal failure related to intravenous immunoglobulin infusion in an elderly woman. Hong Kong Med J 2005; 11: 45-49.
38. Lee YC, Woodfield DG, Douglas R: Clinical usage of intravenous immunoglobulins in Auckland. NZ Med J 1998; 111: 48-50.
39. Metallidis S, Papaioannou M, Bokolas G, Kollaras P, Gogou V, Nikolaidis P: Acute renal failure following intravenous immunoglobulin therapy in a HIV-infected patient. Clin Nephrol 2009; 71: 196-197.
40. Pasatiempo AM, Kroser JA, Rudnick M, Hoffman BI: Acute renal failure after intravenous immunoglobulin therapy. J Rheumatol 1994; 21: 347-349.
41. Tufan F, Kamali S, Erer B, et al: Safety of highdose intravenous immunoglobulin in systemic autoimmune diseases. Clin Rheumatol 2007; 26: 1913-1915.
42. Villarreal IR, Ortega O, Vigil A, et al: Henoch- Schönlein nephritis. Adverse effect of treatment with intravenous immunoglobulin. Nephrol Dial Transplant 1999; 14: 795-797.
43. Tanaka H, Waga S, Tateyama T, Sugimoto K, Kakizaki Y, Yokoyama M: Acute tubulointerstitial nephritis following intravenous immunoglobulin therapy in a male infant with minimal- change nephrotic syndrome. Tohoku J Exp Med 1999; 189: 155-161.
44. Dickenmann M, Oettl T, Mihatsch MJ: Osmotic nephrosis: acute kidney injury with accumulation of proximal tubular lysosomes due to administration of exogenous solutes. Am J Kidney Dis 2008; 51: 491-503.
45. Dorman HR, Sondheimer JH, Cadnapaphornchai P: Mannitol-induced acute renal failure. Medicine (Baltimore) 1990; 69: 153-159.
46. Akhtar I, Bastani B: Acute renal failure and myocarditis associated with intravenous immunoglobulin therapy. Ann Intern Med 2003; 139:W65.
47. Michail S, Nakopoulou L, Stavrianopoulos I, et al: Acute renal failure associated with immunoglobulin administration. Nephrol Dial Transplant 1997; 12: 1497-1499.
48. Welles CC, Tambra S, Lafayette RA: Hemoglobinuria and acute kidney injury requiring hemodialysis following intravenous immunoglobulin infusion. Am J Kidney Dis 2010; 55: 148-151.
49. Arunabh-Arunabh S, Kumar G, Avila V: Acute renal failure induced by intravenous immune globulin. Am Fam Physician 1996; 53: 862-865.
50. Blanco R, Gonzalez-Gay MA, Ibanez D, Sanchez- Andrade A, Gonzalez-Vela C: Paradoxical and persistent renal impairmentin Henoch- Schönlein purpura after high-dose immunoglobulin therapy. Nephron 1997; 76: 247-248.
51. Harden PN, Robertson S, Isles CG, Rodger RS: Post-transplantation renal impairment and intravenous immunoglobulin. Nephrol Dial Transplant 1996; 11: 1896.
52. Ng SK: Intravenous immunoglobulin infusion causing pseudohyponatremia. Lupus 1999; 8: 488-490.
53. Poullin P, Moulin B, Ollier J, Benaicha M, Olmer M, Gabriel B: Renal complications from intravenous immunoglobulins. Role of renal hemodynamic factors (in French). Presse Med 1995; 24: 441-444.
54. Soares SM, Sethi S: Impairment of renal function after intravenous immunoglobulin. Nephrol Dial Transplant 2006; 21: 816-817.
55. Bollee G, Anglicheau D, Loupy A, et al: Highdosage intravenous immunoglobulin-associated macrovacuoles are associated with chronic tubulointerstitial lesion worsening in renal transplant recipients. Clin J Am Soc Nephrol 2008; 3: 1461-1468.
56. Ochs HD, Siegel J: Stabilizers used in intravenous immunoglobulin products: a comparative review. Pharm Pract News, 2010.
57. Weser E, Sleisenger MH: Metabolism of circulating disaccharides in man and the rat. J Clin Invest 1967; 46: 499-505.
58. Burg MB: Coordinate regulation of organic osmolytes in renal cells. Kidney Int 1996; 49: 1684-1685.
59. Burg MB, Ferraris JD, Dmitrieva NI: Cellular response to hyperosmotic stresses. Physiol Rev 2007; 87: 1441-1474.
60. Steffgen J, Kampfer K, Grupp C, Langenberg C, Muller GA, Grunewald RW: Osmoregulation of aldose reductase and sorbitol dehydrogenase in cultivated interstitial cells of rat renal inner medulla. Nephrol Dial Transplant 2003; 18: 2255-2261.
61. Agence Française de Sé curité Sanitaire des Produits de Santé : Notice: Dé nomination du mé dicament. Clairyg 50 mg/ml, solution pour perfusion Immunoglobuline humaine normale (IgIV). 2011;http://afssaps-prd.afssaps.fr/ php/ecodex/notice/N0187072.htm (accessed January 4, 2012).
62. Visweswaran P, Massin EK, Dubose TD Jr: Mannitol-induced acute renal failure. J Am Soc Nephrol 1997; 8: 1028-1033.
63. Weaver A, Sica DA: Mannitol-induced acute renal failure. Nephron 1987; 45: 233-235.
64. Nissenson AR, Weston RE, Kleeman CR: Mannitol. West J Med 1979; 131: 277-284.
65. Goldwasser P, Fotino S: Acute renal failure following massive mannitol infusion. Appropriate response of tubuloglomerular feedback? Arch Intern Med 1984; 144: 2214-2216.
66. Whelan TV, Bacon ME, Madden M, Patel TG, Handy R: Acute renal failure associated with mannitol intoxication. Report of a case. Arch Intern Med 1984; 144: 2053-2055.
67. Berard R, Whittemore B, Scuccimarri R: Hemolytic anemia following intravenous immunoglobulin therapy in patients treated for Kawasaki disease: a report of 4 cases. Pediatr Rheumatol 2012; 10: 10.
68. Daw Z, Padmore R, Neurath D, et al: Hemolytic transfusion reactions after administration of intravenous immune(gamma)globulin: a case series analysis. Transfusion 2008; 48: 1598-1601.
69. Kahwaji J, Barker E, Pepkowitz S, et al: Acute hemolysis after high-dose intravenous immunoglobulin therapy in highly HLA sensitized patients. Clin J Am Soc Nephrol 2009; 4: 1993-1997.
70. European Medicines Agency. Privigen: Procedural steps taken and scientific information after authorisation. 2012. http://www.ema. europa.eu/docs/enGB/documentlibrary/ EPAR-Proceduralstepstakenand scientificinformationafterauthorisation/ human/000831/WC500043299.pdf (accessed June 5, 2012).
71. CSL Behring. Privigen: Summary of product characteristics. 2012. http://www.ema.europa.eu/docs/enGB/documentlibrary/EPAR-ProductInformation/ human/000831/ WC500043077.pdf (accessed June 5, 2012).
72. CSL Behring. Public communication: Health Canada endorsed important safety information on Privigen, immune globulin intravenous (human). 2012. http://www.hc-sc.gc.ca/ dhp-mps/altformats/pdf/medeff/advisoriesavis/ public/2012/privigenpc-cp-eng.pdf (accessed June 5, 2012).
73. Cheng MJ, Christmas C: Special considerations with the use of intravenous immunoglobulin in older persons. Drugs Aging 2011; 28: 729-736.
74. Gardulf A, Nicolay U, Asensio O, et al: Rapid subcutaneous IgG replacement therapy is effective and safe in children and adults with primary immunodeficiencies - a prospective, multi-national study. J Clin Immunol 2006; 26: 77-185.
75. Ochs HD, Gupta S, Kiessling P, Nicolay U, Berger M: Safety and efficacy of self-administered subcutaneous immunoglobulin in patients with primary immunodeficiency diseases. J Clin Immunol 2006; 26: 265-273.
76. Moulis G, Sailler L, Montastruc JL: Reply to the commentary by Onuigbo on the article 'Exposure to inhibitors of the renin-angiotensin system is a major independent risk factor for acute renal failure induced by sucrose- containing intravenous immunoglobulins. A case-control study'. Pharmacoepidemiol Drug Saf 2012; 21:900-901.
77. Onuigbo MA: Exposure to inhibitors of the renin-angiotensin system is a major independent risk factor for acute renal failure induced by sucrose containing intravenous immunoglobulins. A case-control study. Pharmacoepidemiol Drug Saf 2012; 21: 320-322.
78. Cherin P, Cabane J: Relevant criteria for selecting an intravenous immunoglobulin preparation for clinical use. BioDrugs 2010; 24: 211-223.
79. Tonnellier M, Guidet B: Immunoglobulines en reanimation. 1999. http://www.sfar.org/acta/ dossier/archives/ca99/html/ca9940/9940. htm#74694 (accessed June 1, 2012).
80. Prescribing information: Clairyg 50 mg/ml solution pour perfusion. http://www.looksante. fr/medicaments-et-traitements/solution/ clairyg-50-mg-ml-solution-pour-perfusion/ (accessed June 1, 2012).
81. Ramisse F, Deramoudt FX, Szatanik M, et al: Effective prophylaxis of influenza A virus pneumonia in mice by topical passive immunotherapy with polyvalent human immunoglobulins or F(ab ' ) 2 fragments. Clin Exp Immunol 1998; 111: 583-587.
82. Sati HI, Ahya R, Watson HG: Incidence and associations of acute renal failure complicating high-dose intravenous immunoglobulin therapy. Br J Haematol 2001; 113: 556-557.